Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-carb is a polymeric micelle formulation designed to deliver o-carborane, a high-boron-content cage-like compound, for use in Proton Boron Capture Therapy (PBCT). Developed by researchers at UT MD Anderson Cancer Center and the University of Lisboa, M-carb consists of o-carborane entrapped within an amphiphilic block copolymer, forming stable micelles approximately 60 nm in diameter. The mechanism of action relies on the proton-boron fusion reaction (11B + p → 3α + 8.7 MeV), where the uptake of boron by cancer cells followed by proton irradiation leads to the production of alpha particles, significantly enhancing the cell-killing efficacy of proton therapy. In preclinical studies, M-carb demonstrated effective uptake in pancreatic cancer cells (MIA PaCa-2) and increased DNA double-strand breaks upon irradiation, showing superior survival reduction compared to proton therapy alone or standard boron-carrying agents like boron phenylalanine (BPA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on M-carb.